{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T13:59:05Z","timestamp":1794405545568,"version":"4.9.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1C1C1007994, 2021R1C1C1005297, 2020M2D9A2094153, 2020R1A2C1004775"],"award-info":[{"award-number":["2019R1C1C1007994, 2021R1C1C1005297, 2020M2D9A2094153, 2020R1A2C1004775"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Based on the immunologic effects of anti-cancer treatment and their therapeutic implications, we evaluated radiotherapy (RT)-induced dynamic alterations in programmed death-1 (PD-1)\/PD ligand-1 (PD-L1) expression profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Local RT with 2 Gy \u00d7 5 or 7.5 Gy \u00d7 1 was administered to the CT26 mouse model. Thereafter, tumors were resected and evaluated at the following predefined timepoints according to radiation response status: baseline, early (immediately after RT), middle (beginning of tumor shrinkage), late (stable status with RT effect), and progression (tumor regrowth). PD-1\/PD-L1 activity and related immune cell profiles were quantitatively assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>RT upregulated PD-L1 expression in tumor cells from the middle to late phase; however, the levels subsequently decreased to levels comparable to baseline in the progression phase. RT with 2 Gy \u00d7 5 induced a higher frequency of PD-L1+ myeloid-derived suppressor cells, with a lesser degree of tumor regression, compared to 7.5 Gy. The proportion of PD-1+ and interferon (IFN)-\u03b3+CD8\u03b1 T cells continued to increase. The frequency of splenic PD-1+CD8+ T cells was markedly elevated, and was sustained longer with 2 Gy \u00d7 5. Based on the transcriptomic data, RT stimulated the transcription of immune-related genes, leading to sequentially altered patterns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The dynamic alterations in PD-1\/PD-L1 expression level were observed according to the time phases of tumor regression. This study suggests the influence of tumor cell killing and radiation dosing strategy on the tumor immune microenvironment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.989190","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T07:40:06Z","timestamp":1669016406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Dynamic alterations in PD-1\/PD-L1 expression level and immune cell profiles based on radiation response status in mouse tumor model"],"prefix":"10.3389","volume":"12","author":[{"given":"Yi Na","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ho","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonkyoo","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weon Kuu","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug-radiotherapy combinations","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e002038","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657024","article-title":"Nivolumab and hypofractionated radiotherapy in patients with advanced lung cancer: ABSCOPAL-1 clinical trial","volume":"11","author":"Ye","year":"2021","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-2474","article-title":"Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer","volume":"27","author":"Segal","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.799957","article-title":"The research progress of PD-1\/PD-L1 inhibitors enhancing radiotherapy efficacy","volume":"11","author":"Wen","year":"2021","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/19768354.2021.1954550","article-title":"Time-sequential change in immune-related gene expression after irradiation in glioblastoma: next-generation sequencing analysis","volume":"25","author":"Kim","year":"2021","journal-title":"Anim Cells Syst (Seoul)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/cells10040930","article-title":"Biomarkers of radiotherapy-induced immunogenic cell death","volume":"10","author":"Vaes","year":"2021","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2021.00885","article-title":"Immunomodulatory effect of splenectomy in lung cancer mouse xenograft models receiving radiation therapy","volume":"40","author":"Kim","year":"2022","journal-title":"Radiat Oncol J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3857\/roj.2019.00640","article-title":"The emerging role of myeloid-derived suppressor cells in radiotherapy","volume":"38","author":"Kang","year":"2020","journal-title":"Radiat Oncol J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijrobp.2018.01.071","article-title":"Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy","volume":"101","author":"Lan","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3390\/jpm11060527","article-title":"Non-homogeneous tumor growth and its implications for radiotherapy: A phenomenological approach","volume":"11","author":"Castorina","year":"2021","journal-title":"J Pers Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-021-01441-w","article-title":"A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study","volume":"127","author":"Parisi","year":"2022","journal-title":"Radiol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-016-1552-7","article-title":"Stereotactic body radiotherapy in non-operable lung cancer patients","volume":"18","author":"Vadal\u00e0","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/02841860600604611","article-title":"Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma","volume":"45","author":"Wers\u00e4ll","year":"2006","journal-title":"Acta Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211027348","article-title":"Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. the first case report of bystander effect on bone","volume":"28","author":"Parisi","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","article-title":"Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00511","article-title":"Abscopal effects in radio-Immunotherapy-Response analysis of metastatic cancer patients with progressive disease under anti-PD-1 immune checkpoint inhibition","volume":"10","author":"Trommer","year":"2019","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108737","article-title":"Radiation dose and schedule influence the abscopal effect in a bilateral murine CT26 tumor model","volume":"108","author":"Ghaffari-Nazari","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.nhtm.2014.08.001","article-title":"Animal models in translational medicine: Validation and prediction","volume":"2","author":"Denayer","year":"2014","journal-title":"New Horiz Transl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e000464","DOI":"10.1136\/jitc-2019-000464","article-title":"NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer","volume":"8","author":"Walker","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e004218","DOI":"10.1136\/jitc-2021-004218","article-title":"Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7\/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT","volume":"10","author":"Rolig","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606674","article-title":"PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy","volume":"9","author":"Azad","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.3390\/cancers13133290","article-title":"Lattice or oxygen-guided radiotherapy: What if they converge? possible future directions in the era of immunotherapy","volume":"13","author":"Ferini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.837400","article-title":"Ex vivo irradiation of lung cancer stem cells identifies the lowest therapeutic dose needed for tumor growth arrest and mass reduction In vivo","volume":"12","author":"Puglisi","year":"2022","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/2326-6066.Cir-16-0114","article-title":"Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery","volume":"5","author":"Mosely","year":"2017","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.989190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T07:40:08Z","timestamp":1669016408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.989190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":36,"alternative-id":["10.3389\/fonc.2022.989190"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.989190","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fonc.2022.989190.s001","asserted-by":"subject"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"article-number":"989190"}}